findmyKOL

Nancy Bartlett, MD

Enriched profile

Koman Professor of Medical Oncology, Washington University School of Medicine · Washington University School of Medicine

ORCIDNPI
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyMedical OncologyFocusLymphoma
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1998–2026

Nancy Bartlett is Koman Professor of Medical Oncology, Washington University School of Medicine at Washington University School of Medicine. OpenAlex indexes 931 publications with 48,210 citations (h-index 96); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Nancy L. Bartlett, MD, is Koman Professor of Medical Oncology, Washington University School of Medicine. The public record shows 931 publications with 48,210 citations (h-index 96), centered on Lymphoma. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 11 companies, 5 NIH-funded awards (1998–2026).

  • Most recent indexed publication: 2026 · Blood
  • Top research focus: Lymphoma
  • 19 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma19 trialsHodgkin Disease5 trialsLymphoma, Follicular3 trialsLymphoma, Non-Hodgkin3 trialsLymphoma, Large B-Cell, Diffuse3 trialsLymphoma, B-Cell3 trialsLymphoma, Large-Cell, Anaplastic1 trialLymphoma, T-Cell, Cutaneous1 trialLymphoma, T-Cell1 trial

Research focus

OpenAlex concept fingerprint
Lymphoma

Drugs & molecules

across trials, industry payments and publications
Adcetrisgeneric · Brentuximab vedotinClinical trialsIndustry payments1Publications6Lunsumiogeneric · MosunetuzumabClinical trialsIndustry payments1Publications5Rituxangeneric · RituximabClinical trialsIndustry payments1Publications5

Works with

trial sponsors and companies reporting payments
Seagen Inc.Clinical trials1Industry payments1National Cancer Institute (NCI)Clinical trials5Industry paymentsTaiho Oncology, Inc.Clinical trialsIndustry payments4

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
931publications

Distinct works indexed by OpenAlex, matched via ORCID; 49 in PubMed.

48,210citations

Total citations across indexed works.

96h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
19clinical trials

Investigator role on registered studies.

View trials
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
5NIH grants · 1998–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    55.2%
    PD-1 inhibitor44.5%
    Pembrolizumab100%
    Part B, office-administered13 patients
    Kinase inhibitor4.3%
    Brukinsa45%Calquence36%Jaypirca13%Imbruvica7%
    Part D<11 patients
  • Anti-infectives

    10.8%
    Human Immunoglobulin G9%
    Immune globulin100%
    Part B, office-administered13 patients
    Short-acting sulfonamides0.8%
    Sulfamethoxazole-Trimethoprim100%
    Part D24 patients
  • Metabolism & gastrointestinal

    10.8%
    Serotonin-3 Receptor Antagonist7%
    Palonosetron hcl90%Ondansetron Hcl10%
    Part D + Part B45 patients
    Corticosteroid1.6%
    Prednisone100%
    Part D53 patients
10 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

5 NIH research awards on record, funded 19982026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/nancy-bartlett-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/nancy-bartlett-21ba803a

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    hematology.wustl.edu/people/faculty/Bartlett/Bartlett_Bio.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hematology.wustl.edu
3 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/SitemanCancerCenter/posts/washington-university-medical-oncologist-nancy-bartlett-md-who-treats-lymphoma-p/10156845030541412

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • LinkedIn

    linkedin.com/posts/pedalthecause_dr-nancy-bartlett-ptc-featured-fighters-activity-7021505253153849345-0MRv

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Doximity

    Doximity professional profile (auth-walled; confirms St. Louis, MO oncology practice)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    1993
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu
  • Board Certified

    Internal Medicine, American Board of Internal Medicine

    1989
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu
  • MD

    Washington University School of Medicine, St. Louis, MO

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • MS

    Chemical Engineering, Massachusetts Institute of Technology

    1979
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • BS

    Chemical Engineering, Stanford University

    1978
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu

Editorial & leadership roles

journal and society appointments
  • Member

    Scientific Program Committee, American Society of Clinical Oncology (ASCO)

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu
  • Director

    Lymphoma Program, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine (20+ years)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.wustl.edu
  • Chair

    Quality Assurance and Safety Monitoring Committee, Siteman Cancer Center (15+ years)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siteman.wustl.edu
5 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.